NRx and Hungary Agree on Regulatory Path for Emergency Use of ZYESAMI Hungary to Serve as First European Nation for the Registrational Phase 2b/3 BriLife COVID Vaccine Trial
NRx and Hungary Agree on Regulatory Path for Emergency Use of ZYESAMIHungary to Serve as First European Nation for the Registrational Phase 2b/3 BriLife.
StreetInsider com - Corporate News streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Blueprint Medicines Data Highlight Clinical Leadership in Systemic Mastocytosis at AACR Annual Meeting 2021 75% confirmed ORR, with all responses ongoing, in PATHFINDER trial of AYVAKIT in advanced SM New patient-reported outcomes data from PATHFINDER trial show AYVAKIT significantly reduced disease symptoms and improved quality of life BLU-263 was well-tolerated across all doses tested in Phase 1 healthy volunteer trial, supporting plans to initiate Phase 2/3 HARBOR trial in non-advanced SM in mid-2021 Blueprint Medicines to host investor conference call and webcast on Monday, April 12 at 8:00 a.m. ET
News provided by
Share this article
Share this article